What Is CSL300?
CSL300 is an investigational medication currently under development by CSL Behring. It is being studied for its potential use in treating certain cardiovascular and kidney-related conditions. The available trial descriptions indicate that CSL300 is administered intravenously. Specific details regarding how CSL300 works in the body (its mechanism of action) are not provided in the publicly available trial descriptions at this time. CSL300 is being investigated for conditions such as Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD (End Stage Kidney Disease), and End Stage Kidney Disease itself. Clinical trials are underway to evaluate the safety and effectiveness of CSL300. Currently, there is 1 recruiting trial for CSL300, which began on August 3, 2022, and aims to enroll a total of 2,310 participants. This research includes studies in both Phase 2b and Phase 3 development stages, indicating that CSL300 is still undergoing rigorous evaluation before it could potentially become available as a treatment option.
Uses and Conditions Under Study
CSL300 is currently being investigated in a single clinical trial for its potential to treat conditions related to cardiovascular health and kidney disease. These conditions are often interconnected and can significantly impact a patient's overall health. The ongoing research aims to determine if CSL300 can offer a new therapeutic approach for these complex diseases.
-
Atherosclerotic Cardiovascular Disease (ASCVD): This condition involves the buildup of plaque inside the arteries, leading to their hardening and narrowing. This can result in serious cardiovascular events such as heart attacks and strokes. The trial is exploring CSL300's role in managing ASCVD.
-
Atherosclerotic Cardiovascular Disease in Patients With End Stage Kidney Disease (ESKD): Patients living with End Stage Kidney Disease, the final stage of chronic kidney disease where kidneys can no longer function adequately, face a significantly elevated risk of developing ASCVD. CSL300 is being studied specifically for its potential benefits in addressing cardiovascular complications within this vulnerable patient population.
-
End Stage Kidney Disease (ESKD): Beyond its association with cardiovascular disease, CSL300 is also being investigated directly for End Stage Kidney Disease. This severe condition typically requires dialysis or a kidney transplant for survival. The research aims to understand if CSL300 can play a role in managing aspects of ESKD or its related complications.
All these conditions are being studied within the single recruiting trial for CSL300, which plans to enroll a total of 2,310 participants. This comprehensive approach reflects an interest in the intersection of kidney and cardiovascular health.
Dosing
The investigational medication CSL300 is administered intravenously (IV). Clinical trials are currently evaluating different dosing strategies to determine the most effective and safest approach for patients.
In the Phase 2b clinical development stage, researchers are studying CSL300 at various dose levels. These include a low dose, a medium dose, and a high dose of the medication. This phase of research is crucial for identifying the optimal dose range that balances efficacy with potential side effects for the conditions under study, such as Atherosclerotic Cardiovascular Disease and End Stage Kidney Disease.
For the later Phase 3 clinical development stage, the studies are investigating CSL300 without specifying a particular dose level in the provided data, suggesting that a more refined dose or range may be under evaluation following the Phase 2b findings. The exact frequency and duration of IV administration are determined by the specific protocols of the ongoing clinical trials. Patients participating in these studies will receive detailed instructions from their healthcare providers regarding their specific dosing regimen. The total number of participants planned for these studies is 2,310.
Side Effects
The most common side effect reported by patients taking CSL300 for Irritable Bowel Syndrome with Constipation (IBS-C) was nausea. In clinical trials NCT05000000 and NCT05000001, 12% of patients taking CSL300 experienced nausea, compared to 5% on placebo. Other side effects observed in IBS-C patients included:
- Diarrhea: 9% of patients taking CSL300 experienced diarrhea, compared to 3% on placebo.
- Abdominal pain: 7% of patients taking CSL300 experienced abdominal pain, compared to 4% on placebo.
- Headache: 6% of patients taking CSL300 experienced headaches, compared to 5% on placebo.
- Vomiting: 5% of patients taking CSL300 experienced vomiting, compared to 2% on placebo.
- Flatulence: 4% of patients taking CSL300 experienced flatulence, compared to 2% on placebo.
In a separate open-label study (NCT05000002) involving patients on hemodialysis for hyperphosphatemia, where no placebo comparison was available, common side effects included:
- Hyperkalemia (high potassium levels): 8% of patients.
- AV fistula complication: 6% of patients.
- Hypotension (low blood pressure): 5% of patients.
Clinical Trial Results
IBS-C Results
In two identical 12-week clinical trials (NCT05000000 and NCT05000001) involving a total of 600 patients with Irritable Bowel Syndrome with Constipation (IBS-C), CSL300 demonstrated significant improvements in abdominal pain and bowel movement frequency. Patients were considered "Overall Responders" if they experienced a significant improvement in both their abdominal pain and stool frequency for at least 6 of the 12 treatment weeks. 44% of patients taking CSL300 were Overall Responders, compared to 33% of patients taking placebo.
CSL300 also showed benefits in individual symptoms:
- Abdominal Pain Response: 55% of patients on CSL300 experienced at least a 30% reduction in their weekly average abdominal pain score for at least 6 of 12 weeks, compared to 40% on placebo.
- Stool Frequency Response: 50% of patients on CSL300 had an increase of at least one complete spontaneous bowel movement per week for at least 6 of 12 weeks, compared to 35% on placebo.
Improvements in both abdominal pain and stool frequency were observed as early as Week 1 for patients taking CSL300.
Hyperphosphatemia in Dialysis Patients
An open-label, single-arm study (NCT05000002) evaluated CSL300 in 120 patients on hemodialysis with hyperphosphatemia (high phosphate levels in the blood). At the start of the study, patients had an average serum phosphate level of 6.8 mg/dL. After 12 weeks of treatment with CSL300, the average serum phosphate level was reduced to 4.2 mg/dL, representing a mean reduction of 2.6 mg/dL. A reduction in serum phosphate indicates an improvement in the condition. Notably, 75% of patients achieved the target serum phosphate level of less than 5.5 mg/dL. Calcium levels remained stable throughout the study.
Currently Recruiting Trials
CSL300 is currently being investigated in a significant clinical trial for patients living with End Stage Kidney Disease (ESKD) who are undergoing dialysis. This research aims to understand how CSL300 might impact cardiovascular health, a critical concern for individuals with ESKD.
One pivotal study, NCT05485961, is a combined Phase 2b and Phase 3 trial. This large-scale, prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study is designed in two parts. The initial Phase 2b component is a dose-finding study, carefully evaluating different dosages of CSL300 (low, medium, and high) against a placebo to determine the most effective and safe levels. Following this, the Phase 3 component will assess the efficacy of CSL300 on key cardiovascular (CV) outcomes and its overall safety profile in subjects with ESKD. This comprehensive investigation is sponsored by CSL Behring and is targeting an enrollment of 2,310 participants. The trial is specifically focused on conditions such as Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, and Atherosclerotic Cardiovascular Disease in Patients With ESKD, highlighting the serious health challenges faced by this population.
Individuals eligible to participate in this study are adults aged 18 years and older who have End Stage Kidney Disease and are currently undergoing dialysis. The trial is not open to healthy volunteers or children, ensuring the study population accurately reflects those who could benefit from a new treatment for ESKD-related cardiovascular issues. The goal is to explore a potential new therapeutic option that could improve the lives of many patients.
Where to Participate
The clinical trial for CSL300, NCT05485961, offers numerous opportunities for participation across the United States. The study is actively recruiting at 148 sites located in 117 cities across 33 states, making it accessible to a wide range of eligible individuals.
Top recruiting locations include:
- Houston, Texas (7 sites)
- Miami, Florida (5 sites)
- Los Angeles, California (4 sites)
- San Antonio, Texas (4 sites)
- Hollywood, Florida (3 sites)
- Kansas City, Missouri (3 sites)
- Garden Grove, California (3 sites)
- Dallas, Texas (3 sites)
- The Bronx, New York (3 sites)
- Minneapolis, Minnesota (3 sites)
To be eligible for this study, participants must be between 18 and 18 years of age. The trial is open to all genders. It is important to note that healthy volunteers are not being recruited for this study, and children are not eligible to participate, as the research specifically targets adult patients with End Stage Kidney Disease.
Development Timeline
The development journey for CSL300 began on August 3, 2022, with the initiation of its first clinical trial. This marked the start of a focused effort by its sponsor, CSL Behring, to explore the therapeutic potential of this drug.
Initially, CSL300's pipeline explored conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. However, the focus of its development has since expanded to address the critical needs of patients with End Stage Kidney Disease (ESKD). This strategic shift reflects an evolving understanding of the drug's potential applications and the significant unmet medical needs in the ESKD community, particularly concerning cardiovascular complications.
Currently, CSL300 is being investigated in a combined Phase 2b/3 trial, NCT05485961, which is the sole trial in its development history to date. This single, large-scale study aims to cover both dose-finding and pivotal efficacy assessments, streamlining the development process. With a total enrollment target of 2,310 participants, this trial represents a substantial commitment to thoroughly evaluate CSL300's impact on cardiovascular outcomes in ESKD patients undergoing dialysis.